Premium
Post‐licensing safety of fosamprenavir in HIV‐infected children in Europe
Author(s) -
Judd Ali,
Duong Trinh,
Galli Luisa,
Goetghebuer Tessa,
Ene Luminita,
Julian Antoni Noguera,
Amador Jose Tomas Ramos,
Pimenta Jeanne Marie,
Thorne Claire,
Giaquinto Carlo
Publication year - 2014
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.3543
Subject(s) - medicine , virology , human immunodeficiency virus (hiv) , pharmacoepidemiology , environmental health , pharmacology , medical prescription
Purpose Fosamprenavir, combined with low‐dose ritonavir (FPV/r), is indicated for treatment of HIV‐infected children aged ≥6 years in Europe. Our purpose was to assess the safety of licensed use of FPV/r in HIV‐infected children reported to six cohorts in the European Pregnancy and Paediatric HIV Cohort Collaboration. Methods Retrospective analysis of individual patient data for all children aged 6–18 years taking the licensed dose of FPV up to 31/12/10. Adverse events (clinical events and absolute neutrophil counts, total cholesterol and triglycerides, and alanine transaminase) were summarised and DAIDS gradings characterised severity. Results Ninety‐two HIV‐infected children aged 6–18 years took the licensed dose, comprising 3% of the total number of children in follow‐up in participating cohorts. Median age at antiretroviral therapy initiation was 6 years (interquartile range 1–11 years), and median age at start of FPV/r was 15 years (12–17 years). Estimated median time on an FPV‐containing regimen was 52 months, with a total of 266.9 patient years of exposure overall. Half (54%) were on an FPV‐containing regimen at last follow‐up. Rates of grade 3/4 events were generally low for all biochemical toxicity markers, and no serious adverse events considered to be causally related to FPV/r were reported. Conclusions Results suggest that long‐term licensed dose FPV‐containing regimens appear to be generally well tolerated with few reported toxicities in HIV‐infected children in Europe, although relatively infrequently prescribed. No serious events were reported. © 2013 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.